<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Jayol, Aurélie</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:creator>Poirel, Laurent</dc:creator>
  <dc:creator>Dubois, Véronique</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The spread of carbapenemase-producing Klebsiella pneumoniae is a major public  health concern since such isolates are basically resistant to most available antibiotics,  including β-lactams, fluoroquinolones and aminoglycosides.1 Infections due to  carbapenemase-producing K. pneumoniae are therefore commonly treated with a  regimen containing colistin.1 However, acquired resistance to colistin now occurs  frequently and has few therapeutic options.2 Outbreaks with colistin-resistant and  carbapenemase-producing K. pneumoniae isolates have been reported worldwide2  and mortality rates are high owing to limited treatment options.3...Recently, a new  therapeutic option, namely ceftazidime/avibactam, combining a broad-spectrum  cephalosporin and a novel β-lactamase inhibitor, has been marketed. The addition of  avibactam expands the spectrum of activity of ceftazidime to many MDR  Enterobacteriaceae including producers of ESBLs and carbapenemases.4...</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/unifr/documents/306213</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/306213/files/nor_caa.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/306213/files/nor_caa_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkx393</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of Antimicrobial Chemotherapy. - 2018, vol. 73, no. 2, p. 542-544</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
